Production houses use these alphanumeric systems (often consisting of a three or four-letter prefix followed by a numerical sequence) to streamline inventory management and help consumers locate specific content. In this case, "JUQ" represents the specific label or series brand, while "279" denotes the chronological release number within that series. Industry Context and Distribution
Cons: [Insert cons or disadvantages]
Pharmacological Research
"JUQ-279 - This identifier is associated with [insert description here]. Further details can be found [where, e.g., in a database, on a website]."
In the vast and intricate world of research chemicals, certain compounds manage to capture the attention of scientists and researchers due to their unique properties and potential applications. One such compound that has been gaining interest in recent years is JUQ-279. This article aims to provide an in-depth exploration of JUQ-279, shedding light on its chemical structure, potential uses, and the importance of responsible handling and research practices. JUQ-279
Introduction: [Insert brief introduction or overview of the product]
Challenges and Future Directions
Results: JUQ‑279 displayed sub‑nanomolar inhibition of PI3K‑β (Kᵢ = 0.42 nM) and >200‑fold selectivity over PI3K‑α, -δ, -γ, and a >1,000‑fold window versus a panel of >450 off‑target kinases. In TNBC cells, JUQ‑279 reduced p‑AKT (Ser473) and p‑S6K (Thr389) within 30 min (IC₅₀ ≈ 15 nM). Dose‑dependent cytotoxicity was observed (mean IC₅₀ = 73 nM) with G₁ arrest and induction of caspase‑3/7 activity (2.8‑fold over control). RNA‑seq revealed down‑regulation of MYC‑target genes and up‑regulation of pro‑apoptotic BCL2‑family members. In orthotopic xenografts, oral JUQ‑279 (30 mg kg⁻¹ qd) achieved 78 % tumor growth inhibition (TGI) (p < 0.001) and prolonged median survival from 31 days (vehicle) to >70 days. The PDX cohort showed a 62 % objective response rate (≥30 % reduction). Pharmacokinetic profiling demonstrated a Cmax of 4.8 µM, half‑life of 6.4 h, and >90 % oral bioavailability. No Grade ≥ 2 toxicities were observed; the no‑observed‑adverse‑effect level (NOAEL) was ≥150 mg kg⁻¹ qd.
